Home / 2021 / February / 02

Daily Archives: February 2, 2021

Gianfranco Battisti, Ferrovie dello Stato Italiane CEO, makes an analysis of the Group

The Italian State Railways has embarked becoming a leading global reference point in its sector

GIANFRANCO BATTISTI, CEO of Ferrovie dello Stato Italiane Group

GIANFRANCO BATTISTI, CEO of Ferrovie dello Stato Italiane Group

ROME, Feb. 02, 2021 (GLOBE NEWSWIRE) — The Ferrovie dello Stato Italiane Group (FS Group, i.e. the Italian State Railways) has embarked, particularly in recent years, on a significant process aimed at strengthening its position on foreign markets, becoming a leading global reference point in its sector, both in terms of the results achieved and the level of professionalism associated with the use of innovative technologies.

In 2019, the international activity carried out by the FS Group generated revenues of approximately €1.8 billion, equal to around 14% of its total turnover. The share of revenues relating to the European market makes up approximately 94% of the Group’s foreign turnover.

The 2019–2023 Industrial Plan, based on the above-mentioned market positioning and the prospects for growth in the international market, calls for a greater commitment beyond national borders.

The skills made available to the international market involve all components of the value chain, from Transport Master Plans and feasibility and design studies, to works supervision, certification, Operation & Maintenance of networks, rolling stock and stations and intermodal hubs.

The Group’s international presence is guaranteed by the direct commitment of several companies in Italy and abroad, where FS is present with 22 offices across five continents.

The initiatives of the subsidiaries are constantly supported by the activities of the parent company, which develops international institutional relations, also aimed at promoting the business of its subsidiaries: at present, 12 international cooperation agreements have been signed by Ferrovie dello Stato Italiane, either directly or through its operating subsidiaries.

The European market is the “new domestic market” for our transport companies: in this wider competitive context, the knowledge and excellence achieved by the Group in the Italian high-speed sector will be winning factors for the growth and strengthening of our companies.

Several companies of the FS Group are already active in Europe, mainly engaged in railway passenger transport and freight services. Among these are Netinera and TX Logistik in Germany, Trenitalia UK – with its subsidiaries c2c and First Trenitalia West Coast – in the United Kingdom, Thello in France, Ilsa in Spain, Trainose in Greece and QBuzz in the Netherlands.

On international markets, the Group’s presence is ensured by the activities of FS International, Italferr and Italcertifer, respectively operating in the Operation & Maintenance (O&M), engineering and certification sectors.

Here is a short list of the most recent and important international contracts:

FS International:
Saudi Arabia – 4 lines of the Riyadh metro and O&M
Thailand – high-speed rail network linking three major airports

USA – Texas High Speed Rail, design and works supervision
India – metro lines between Kanpur and Agra
Colombia – metro line in Bogotá
Turkey – two tunnels under the Bosporus
Peru – lines 2 and 4 of the Lima metro/Trans-Andean Tunnel (45 km tunnels)
Egypt – upgrading of line 1 of the Cairo metro
Ethiopia – national master plan commissioned by the Ethiopian Ministry of Transport

Assessment and certification contracts in Saudi Arabia, United Arab Emirates, India and Australia.

For further information:
LaPresse SpA Communication Area Manager
Barbara Sanicola barbara.sanicola@lapresse.it T +39 02 26305578 M +39 333 3905243

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/cb9739b5-4aac-41a3-94d3-1f3bf9bd2a79

Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences

REDWOOD CITY, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) — A day after announcing their new immuno-oncology collaboration, Coherus BioSciences, Inc. (Nasdaq: CHRS) (“Coherus”) announced that Shanghai Junshi Biosciences Co., Ltd (HK: 1877; SH: 688180) (“Junshi Biosciences”) intends to make a strategic investment of $50 million in Coherus pursuant to the terms of the definitive stock purchase agreement.

“We view our collaboration with Coherus as a strategic long-term partnership for the development and commercialization of toripalimab and promising PD-1 combination candidates,” said Dr. Ning LI, CEO of Junshi Biosciences. “We wanted to invest in Coherus so we could share our future growth together and mutual success with these programs.”

“We appreciate this vote of confidence and commitment in Coherus, and we are pleased to have Junshi Biosciences as a partner and now also as a shareholder,” said Denny Lanfear, CEO of Coherus.

Closing of the strategic investment is subject to obtaining requisite market and securities authorities approvals and to clearance under the Hart-Scott Rodino Antitrust Improvements Act.

About Junshi Biosciences

Founded in December 2012, Junshi Biosciences (HK: 1877; SH: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising 27 innovative drug candidates and two biosimilars, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for an anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA antibody for solid tumors was the first in the world to be approved for clinical trials by the FDA and NMPA, and its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA. In early 2020, Junshi Biosciences joined forces with the Institute of Microbiology Chinese Academy of Science and Eli Lilly to co-develop JS016, China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2, which has entered clinical trials and is now a part of the company’s continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou). For more information, please visit: http://junshipharma.com.

About Coherus BioSciences, Inc.

Coherus is a commercial stage biopharmaceutical company with the mission to increase access to cost-effective medicines that can have a major impact on patients’ lives and to deliver significant savings to the health care system.

On February 1, 2021, Coherus and Junshi Biosciences announced a collaboration in which Coherus would in-license toripalimab, an anti-PD-1 antibody, in the United States and Canada. Coherus’ strategy is to build a leading immuno-oncology franchise funded with cash generated by its commercial biosimilar business. Coherus markets UDENYCA® (pegfilgrastim-cbqv) in the United States and through 2023 expects to launch biosimilars of Humira®, Avastin® and Lucentis®, if approved.

For additional information, please visit www.coherus.com.

UDENYCA® is a trademark of Coherus BioSciences, Inc.
Avastin® and Lucentis® are registered trademarks of Genentech, Inc.
Humira® is a registered trademark of AbbVie Inc.

Forward-Looking Statements

Except for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Coherus’ and Junshi Biosciences’ ability to co-develop toripalimab, and Coherus’ ability to commercialize toripalimab, or any other drug candidates developed as part of its collaboration with Junshi Biosciences in the licensed territory; Coherus’ ability to prepare for projected launches through 2023 of biosimilars of Humira®, Avastin® and Lucentis®, if approved.

Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risk that the parties are unable to obtain clearance under the Hart-Scott Rodino Antitrust Improvements Act, from the Committee on Foreign Investment in the United States, or any other statute or regulatory agency having jurisdiction with respect to the proposed transactions, the risks and uncertainties inherent in the clinical drug development process; the risks and uncertainties of the regulatory approval process, including the timing of Coherus’ regulatory filings; the risk that Coherus is unable to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus’ drug candidates; and the risks and uncertainties of possible patent litigation. All forward-looking statements contained in this press release speak only as of the date on which they were made. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission on February 27, 2020, its Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2020, filed with the Securities and Exchange Commission on November 5, 2020 and its future periodic reports to be filed with the Securities and Exchange Commission. Our results for the quarter ended September 30, 2020 are not necessarily indicative of our operating results for any future periods.


McDavid Stilwell
EVP, Financial Strategy and IR
Coherus BioSciences, Inc.
+1 (650) 395-0152

Epiq Helps Reduce Case Preparation Time and Cost with Launch of Advanced Early Case Assessment Offering

NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) — Epiq, a global technology-enabled services leader to the legal services industry and corporations, announced today its launch of Epiq Case Insights™, a new full-service early case assessment (ECA) service offering for corporate law departments and firms.

Now, more than ever, law departments are looking for ways to reduce costs. With over 90% of all court cases settling out of court, early assessment of the facts for a case can greatly reduce litigation costs by allowing a party to pursue a favorable resolution earlier in a matter. With Case Insights, Epiq pairs skilled consultants and analysts with artificial intelligence (AI) to find early insights, hot documents, and valuable facts at the start of a discovery effort.

Through this new offering, experienced Epiq consultants—with deep knowledge of how to use advanced tools, techniques, workflow, and processes—will deliver a report containing key facts and behavior patterns that can help inform case strategy and tactical decisions. As a side benefit, the analysis can identify some tranches of documents clearly not relevant to the matter, which can reduce the overall volume of documents hosted and reviewed.

“We’re always looking for ways to apply advanced technologies, especially AI, to streamline and improve the way legal work gets done. By using AI to turn unstructured data into insights, we’re able to identify data anomalies or issues more quickly and accurately early on in a case,” said Eric Crawley, vice president, global advanced technologies and managed review.

“Our clients also find that due to our eDiscovery and managed review expertise, we’re able to provide in-depth data analysis early on in a case in a highly efficient way. This is another way we are helping them to transform the business of law, especially in today’s challenging environment.”

To learn more about Case Insights, see Epiq’s Legalweek(year) 2021 facilitated in-booth discussion on Wednesday, February 3 at 10:15 AM ET here.

About Epiq

Epiq, a global leader in the legal services industry, takes on large-scale, increasingly complex tasks for corporate counsel, law firms, and business professionals with efficiency, clarity, and confidence. Clients rely on Epiq to streamline the administration of business operations, class action and mass tort, court reporting, eDiscovery, regulatory, compliance, restructuring, and bankruptcy matters. Epiq subject-matter experts and technologies create efficiency through expertise and deliver confidence to high-performing clients around the world. Learn more at www.epiqglobal.com.

Press Contact
Catherine Ostheimer
+1 203 921 9700

Epiq Launches Epiq Empower, an eDiscovery Center of Excellence Consultancy

Helping Corporate Legal Teams Create an In-House Center of Excellence for eDiscovery

NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) — Epiq, a global technology-enabled services leader to the legal services industry and corporations, announced today its launch of Epiq Empower: Your Discovery Center of Excellence. Epiq Empower is a configurable framework built on industry best practices and is designed to help corporate law departments to manage their eDiscovery program with a focus on governance, defensibility, risk mitigation and a predictable cost of ownership.

Epiq Empower provides a consultative approach to establishing or expanding a corporation’s discovery program that provides transparency into quantified efficiencies and spend metrics to effectively manage their eDiscovery portfolio. Our consultants work to design, build, and implement a center of excellence that is tailored to the client’s specific needs, while providing continuous oversight throughout the partnership. Creating a personalized program will help clients onboard best-in-class discovery processes and technologies. The client’s Empower team is their advocate and trusted partner in transforming their eDiscovery process.

With decades of experience working with law departments of Fortune 500 companies, our Empower team will design a configurable framework in collaboration with the client’s legal teams to empower a best-in-class Discovery Center of Excellence consisting of four key elements:

  • Program management: A dedicated team of Epiq discovery experts, personalized playbooks, tailored reporting, and client experience oversight and program compliance to support discovery projects from start to finish.
  • Intelligent data management: Microsoft based data governance tools, legal hold, and preservation, advanced ECA, and analytics.
  • Core discovery services: Technology focused outcomes, consultant driven services which helps teams to use cross-matter intelligence, establish repeatable workflows for small matters, and benefit from ongoing educational programs.
  • Advanced discovery services: Includes advanced attorney services that extend beyond review and deliver operational excellence.

“Our Epiq Empower program is our latest example of how we are helping to transform the business of law,” said Eric Gonzales, senior vice president, of Epiq’s Legal Solutions business. “We are putting our decades of discovery expertise to work for law department leaders interested in improving governance and defensibility while establishing KPIs and metrics that are designed to measure the efficiency and spend of discovery to drive better outcomes, which is vital for today’s challenging economic environment.”

Epiq’s corporate clients include nearly half of the Fortune 100 and nine of the top ten U.S. banks. Their teams have over two decades of eDiscovery experience working with leading companies and law firms globally.

To learn more about Epiq Empower and you are registered for Legalweek(year) 2021, attend our in-booth discussion on Wednesday, February 3, at 2:15 PM ET here.

About Epiq

Epiq, a global leader in the legal services industry, takes on large-scale, increasingly complex tasks for corporate counsel, law firms, and business professionals with efficiency, clarity, and confidence. Clients rely on Epiq to streamline the administration of business operations, class action and mass tort, court reporting, eDiscovery, regulatory, compliance, restructuring, and bankruptcy matters. Epiq subject-matter experts and technologies create efficiency through expertise and deliver confidence to high-performing clients around the world. Learn more at www.epiqglobal.com.

Press Contact
Catherine Ostheimer
+1 203 921 9700

Nasdaq Agrees to Sell U.S. Fixed Income Business to Tradeweb Markets

NEW YORK, Feb. 02, 2021 (GLOBE NEWSWIRE) — Nasdaq, Inc. (Nasdaq: NDAQ) announced today that it has entered into a definitive agreement to sell its U.S. fixed income business, Nasdaq Fixed Income (NFI), to an affiliate of Tradeweb Markets Inc. (Nasdaq: TW), a leading global operator of electronic marketplaces for rates, credit, equities and money markets.

“Tradeweb Markets is the right partner for NFI, as the combined offering is well positioned to serve growing investor needs and creates a comprehensive suite of best in class execution solutions for all market participants,” said Tal Cohen, Executive Vice President and head of North American Markets, Nasdaq.

NFI has successfully repositioned itself in the U.S. Treasuries market, developing and launching new technology and product offerings, which will benefit Tradeweb’s ability to meet its clients’ needs going forward. The decision to sell NFI aligns with Nasdaq’s corporate strategy to concentrate its resources and capital to maximize its potential as a major technology and analytics provider to the global capital markets.

Financial Impact:

As previously disclosed in Nasdaq’s current and periodic reports, Nasdaq has a contingent obligation to issue 992,247 shares of Nasdaq common stock to BGC Partners, L.P. or its assignees every year through 2027 as set forth in the original purchase agreement associated with Nasdaq’s 2013 acquisition of the business. Upon the closing of the sale of NFI, the aggregate number of Nasdaq shares that remain subject to this contingent obligation is expected to be reduced (pursuant to the discounting adjustment provisions set forth in the original purchase agreement for Nasdaq’s acquisition of the business) and accelerated, which would result in an issuance to BGC or its assignees of an aggregate of approximately 6.2 million shares of Nasdaq in 2021.

Nasdaq intends to use the proceeds from the sale of NFI, available tax benefits and NFI working and clearing capital, as well as other sources of cash to repurchase shares in order to offset dilution to non-GAAP earnings per share, or EPS.  The proceeds from the sale, the remaining tax benefits related to the 2013 purchase, and the working and clearing capital to be released upon closing of the transaction are estimated to total approximately $700 million.

To facilitate these repurchases, the Nasdaq’s Board of Directors has authorized an increase to the share repurchase program of an additional $1 billion, subject to the closing of the NFI sale and acceleration of the share issuance to BGC or its assignees. Nasdaq does not expect to increase its leverage as a result of the share repurchases related to this transaction and intends to continue with its previously announced de-leveraging plans following the closing of the Verafin acquisition.

After giving effect to these repurchases, Nasdaq expects this transaction to be 2% dilutive to non-GAAP EPS in the twelve-month period after its closing and does not expect material dilution in subsequent periods.

Nasdaq Fixed Income contributed approximately $23 million in revenue during the twelve-month period ending December 31, 2020.

The transaction is expected to close later in 2021 subject to the satisfaction of customary closing conditions, including the receipt of required regulatory approvals.


Morgan Stanley & Co. LLC is acting as exclusive financial advisor and Skadden, Arps, Slate, Meagher & Flom LLP is acting as counsel to Nasdaq.

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.


In this press release, Nasdaq presents forward-looking estimates for non-GAAP EPS. Management uses this non-GAAP information internally, along with U.S. GAAP information, in evaluating our performance and in making financial and operational decisions. We believe our presentation of this measure provides investors with useful information, greater transparency and supplemental data relating to our financial condition and results of operations, including with respect to management’s expectations regarding the impact of the planned transaction.

This measure is not in accordance with, or an alternative to, U.S. GAAP, and may be different from non-GAAP measures used by other companies. In addition, other companies, including companies in our industry, may calculate such measures differently, which reduces their usefulness as comparative measures. Investors should not rely on any single financial measure when evaluating our business. This non-GAAP information should be considered as supplemental in nature and is not meant as a substitute for our operating results in accordance with U.S. GAAP.

Nasdaq does not provide a GAAP EPS outlook or reconciliation of non-GAAP EPS to GAAP EPS in this press release because changes in the items that Nasdaq excludes from GAAP EPS to calculate non-GAAP EPS can be dependent on future events that are less capable of being controlled or reliably predicted by management and are not part of Nasdaq’s routine operating activities.  The combined impact and timing of recognition of these potential charges or gains is inherently uncertain and difficult to predict and is unavailable without unreasonable efforts.  In addition, Nasdaq believes such reconciliations would imply a degree of precision and certainty that could be confusing to investors.  Such items could have a substantial impact on GAAP measures of financial performance.


This communication contains forward-looking information related to Nasdaq and the proposed sale of the Nasdaq Fixed Income business by Nasdaq to an affiliate of Tradeweb Markets, which transaction involves substantial risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed or implied by such statements. When used in this communication, words such as “will”, “enable”, “intends”, “expected” and similar expressions and any other statements that are not historical facts are intended to identify forward-looking statements. Forward-looking statements in this communication include, among other things, statements about the potential benefits of the proposed transaction, including statements relating to expectations of future operating results and financial performance, the financial condition, results of operations and business of Nasdaq, the anticipated timing of closing of the proposed transaction, and the use of proceeds from the proposed transaction. Risks and uncertainties include, among other things, risks related to the ability of Nasdaq to consummate the proposed transaction on a timely basis or at all; Nasdaq’s ability to secure regulatory approvals on the terms expected, in a timely manner or at all; the ability to realize the anticipated benefits of the proposed transaction, including the possibility that the expected benefits from the proposed transaction will not be realized or will not be realized within the expected time period; disruption from the transaction making it more difficult to maintain business and operational relationships; risks related to diverting management’s attention from Nasdaq’s ongoing business operations; the negative effects of the announcement or the consummation of the proposed transaction on the market price of Nasdaq’s common stock or on Nasdaq’s operating results; significant transaction costs; unknown liabilities; the risk of litigation or regulatory actions related to the proposed transaction; future levels of Nasdaq’s indebtedness, including additional indebtedness that may be incurred in connection with the proposed transaction; and the effect of the announcement or pendency of the transaction on Nasdaq’s business relationships, operating results, and business generally.

Further information on these and other risks and uncertainties relating to Nasdaq can be found in its reports filed on Forms 10-K, 10-Q and 8-K and in other filings Nasdaq makes with the SEC from time to time and available at www.sec.gov. These documents are also available under the Investor Relations section of Nasdaq’s website at http://ir.nasdaq.com/investor-relations. The forward-looking statements included in this communication are made only as of the date hereof. Nasdaq disclaims any obligation to update these forward-looking statements, except as required by law.


Media Contact

Joe Christinat
(646) 441-5121
(646) 284-5920

Alpine Optoelectronics Delivers Single-Wavelength 100G DWDM QSFP28 PAM4 Transceiver for 100km Interconnects

Enabled by nCP4™ Silicon Photonics Optical Engine

100G DWDM QSFP28 PAM4 Optical Transceiver


Alpine Optoelectronics’ Single-Wavelength 100G DWDM QSFP28 PAM4 module supports 100km, 4.8Tbps single fiber links and is compatible with standard 100GHz Mux/Demux, EDFA, and DCM.

FREMONT, Calif., Feb. 02, 2021 (GLOBE NEWSWIRE) — Alpine Optoelectronics, Inc., a leading innovator of optical networking technology, is delivering beta samples of a new Single-Wavelength 100G DWDM QSFP28 transceiver based on its nCP4™ Silicon Photonics Optical Engine, a proprietary Silicon Photonics PAM4 modulator platform developed in-house (patents pending). The module operates at 40 fixed wavelengths on the ITU-T C-band DWDM 100GHz grid and is compatible with standard 40-channel 100GHz spacing DWDM Mux/Demux filters to provide 4Tbps of data capacity over a single G.652 single-mode fiber (SMF). With a link budget up to 25dB, it supports transmission distances of 100km or more in amplified and dispersion compensated systems. For direct links, the product supports up to 8dB link budget for short reaches of 0-2km. For applications requiring even greater bandwidth, the number of available wavelengths is expandable to 48 channels to achieve 4.8Tbps of data capacity.

Live demonstrations of this new 100G DWDM QSFP28 PAM4 transceiver are available as follows:

Demo 1: Single-span 120km multi-channel 100G DWDM transmission over standard SMF with total fiber link insertion loss of 25dB. Standard erbium-doped fiber amplifiers and dispersion compensation modules are used in this demonstration.

Demo 2: Direct link over 2km standard SMF for multi-channel 100G DWDM transmission with average link insertion loss per channel of approximately 7.5dB (including the 6dB average insertion loss per channel of the 40-channel DWDM Mux/Demux pair).

Compared to coherent 100G DWDM transceivers, Alpine’s 100G DWDM QSFP28 PAM4 module offers a disruptive price point and considerably lower power consumption for high-speed extended reach data center interconnects (DCI) and high-density intra-datacenter connectivity. In addition, inherent low latency makes it favorable for delay sensitive applications, such as edge computing and financial networking.

“Silicon Photonics technology reached maturity and wide acceptance in the market by 2021,” commented Dr. Vladimir Kozlov, CEO of LightCounting, “but performance of devices based on this technology continues to surprise us. Alpine’s latest product sets another new record in performance and there are probably more to come.”

“Alpine Optoelectronics is proud to deliver our new 100G DWDM QSFP28 PAM4 transceiver to our strategic partners serving the DCI and intra-datacenter marketplace, and they are impressed with the outstanding performance enabled by our nCP4™ Silicon Photonics platform,” said Tongqing Wang, President and CEO of Alpine Optoelectronics. “Building upon our strong success with 40G DWDM QSFP+ PAM4 optics already in mass production and our deep understanding of DWDM systems, this new 100G DWDM QSFP28 transceiver offers our customers and partners a clear, cost-effective, and flexible path to higher-speed and higher-density optical networking solutions.”

Key Features of the nCP4™ DWDM Solution

  • Single-wavelength 100Gbps optical transmission
  • Fixed wavelengths on the ITU-T C-band 100GHz DWDM grid
  • Up to 4.8Tbps data capacity over a single fiber
  • Compatible with standard 100GHz DWDM Mux/Demux filters
  • 100km reach over SMF with EDFA & DCM
  • PAM4 optical signal with integrated FEC
  • 4.5W power dissipation
  • 4×25.78G CAUI-4 host interface
  • Compliant with QSFP28 MSA SFF-8636
  • QSFP28 MSA digital monitoring functions
  • Supports 100G Ethernet DWDM applications

Alpine Optoelectronics plans to showcase this and other optical connectivity solutions in Booth #2831 at OFC 2021 in San Francisco, California from June 8-10.

About Alpine Optoelectronics
Alpine Optoelectronics, Inc. is a US-based innovator in photonic products, headquartered in Fremont, California. The company was founded in 2017 by industry veteran entrepreneurs with extensive experience in optical transceiver design, development, and manufacturing. The company’s core competencies center on Silicon Photonics, PAM4, and Coherent technology bringing advanced solutions for next generation optical networks. The company is backed by private and strategic investors.

nCP4 is a trademark of Alpine Optoelectronics, Inc.

For more information visit Alpine Optoelectronics at www.alpineoptoelectronics.com or email us at sales@alpineoptoelectronics.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/85a0b297-5d77-42d6-93b9-d3f9c6385611

Philips introduces ClarifEye Augmented Reality Surgical Navigation to advance minimally-invasive spine procedures

February 2, 2021

  • Industry-first image-guided therapy solution combines imaging and augmented reality navigation into one system in the Hybrid Operating Room
  • Unique 3D visualization technology – fully integrated in Philips’ Azurion platform – provides live feedback for accurate spine procedures
  • Intra-operative guidance has been shown to increase clinical accuracy, with patients subject to fewer revision surgeries compared to the current standard of care [1,2]

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today introduced ClarifEye Augmented Reality Surgical Navigation, an industry-first solution to advance minimally-invasive spine procedures in the Hybrid Operating Room, such as Philips’ Hybrid Suite. By combining superb 2D and 3D visualizations at low X-ray dose [3] with 3D augmented reality (AR), the unique solution provides live intra-operative visual feedback to support accurate placement of pedicle screws during spinal fusion procedures. During such procedures, two or more vertebrae in the spine are permanently connected to help improve stability, correct a deformity, or reduce pain. The solution is fully integrated into the Philips Azurion image-guided therapy platform, supporting efficient workflow with intra-procedural navigation and verification for accurate screw placement and reducing the need for post-operative CT scans.

Spine conditions can have a significant impact on quality of life and well-being, with severe cases leaving patients unable to walk or even move from their beds. Treatment is typically complex and delicate, with surgeons required to take particular care to avoid fragile neurological and vascular structures that are close to the spine. By taking a minimally-invasive approach to spine surgery, patients can benefit from reduced postoperative pain, shortened hospital stays, reduced blood loss, and minimized soft tissue damage and scar tissue [4]. In addition, the intra-operative image guidance provided by solutions such as ClarifEye increases clinical accuracy, with patients subject to fewer revision surgeries compared to the current standard of care [1,2].

“In spine surgery, when you change your approach to a minimally invasive one, you also have to change the way you operate because you need another way to see inside the spine,” said Dr. Pietro Scarone, neurosurgeon at Ente Ospedaliero Cantonale in Lugano, Switzerland. “With ClarifEye, the technology adapts to the needs of the surgeon, rather than the surgeon adapting to the requirements of the technology.”

“Augmented reality surgical navigation helps us to place pedicle screws in positions where we actually couldn’t or wouldn’t do otherwise,” said Dr. Adria Elmi-Terander, neurosurgeon in the department of Neurosurgery at the Karolinska University Hospital in Stockholm, Sweden.

Four high-resolution optical cameras are used to augment the surgical field with 3D cone-beam CT imaging, without the need for additional X-ray. The system combines the view of the surgical field with the internal 3D view of the patient to construct a 3D augmented-reality view of the patient’s external and internal anatomy. Consistent tracking of the patient is ensured by video tracking of non-invasive markers placed on the skin. The system then visualizes the tip of the ClarifEye Needle as it is navigated along the planned path in the spine.

“Post-operative CT scans to check implant placements are no longer necessary,” said Prof. Dr. Andreas Seekamp, Director of the Orthopaedic and Emergency Surgery clinic at the University Medical Center Schleswig-Holstein in Kiel, Germany. “As soon as surgery has been performed, we can be 100% sure that the implants are in place, thanks to the high quality of the intra-operative cone beam CT image and positioning flexibility of the system.”

“Through co-creation with our clinical partners we’ve developed an innovative integrated solution that has the potential to improve outcomes and reduce costs for minimally invasive spine procedures,” said Ronald Tabaksblat, General Manager Image Guided Therapy Systems at Philips. “With ClarifEye we are delivering on our strategy of expanding minimally invasive surgery into new clinical areas. The solution is built on the Philips next-generation Azurion image-guided therapy platform, enabling an unmatched level of integration and an intuitive experience for clinicians.”

To learn more from physicians using advanced imaging and navigation solutions in spine surgeries, register here for the educational webinar taking place on Thursday, March 11th at 3:00pm CET.

For more information on Philips’ approach to bringing AR to minimally-invasive spine surgery, read this Q&A with Ronald Tabaksblat.

ClarifEye Augmented Reality Surgical Navigation is CE marked and 510(k) pending. This material is not for distribution in the U.S.A.

[1] Dea N, Fisher CG, Batke J, Strelzow J, Mendelsohn D, Paquette SJ, Kwon BK, Boyd MD, Dvorak MFS, Street JT. Economic evaluation comparing intraoperative cone beam C T based navigation and conventional fluoroscopy for the placement of spinal pedicle screws: a patient level data cost effectiveness anal ysis. The Spine Journal (2016) 16: 23 31.
[2] Fichtner J, Hofmann N, Rienmüller A, Buchmann N, Gempt J, Kirschke JS, Ringel F, Meyer B, Ryang Y M. Revision Rate of Misplaced Pedicle Screws of the Thoracolumbar SpineeComparison of Three Dimensional Fluoroscopy Navigation with Freehand Placement: A Systematic Analysis and Review of the Literature. World Neurosurg . (2018) 109: e24 e32.
[3] Nachabe R, Strauss K, Schueler B, Bydon M. Radiation dose and image quality comparison during spine surgery with two different, intraoperative 3D imaging navigation systems, J Appl Clin Med Phys 2019 Feb; 20(2): 136-145.
[4] Phan K, Rao PJ, Mobbs RJ. Percutaneous versus open pedicle screw fixation for treatment of thoracolumbar fractures: Systematic review and meta-analysis of comparative studies. Clinical neurology and neurosurgery. 2015. 135:85-92.

For further information, please contact:

Mark Groves
Philips Global Press Office
Tel.: +31 631 639 916
E-mail: mark.groves@philips.com

Fabienne van der Feer
Philips Image Guided Therapy
Tel: + 31 622 698 001
E-mail : fabienne.van.der.feer@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being, and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2020 sales of EUR 19.5 billion and employs approximately 82,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.